Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $34.8 million.

  • Lifecore Biomedical, Inc. \De\'s Shares Outstanding (Weighted Average) rose 1425.66% to $34.8 million in Q2 2025 from the same period last year, while for May 2025 it was $34.8 million, marking a year-over-year increase of 1425.66%. This contributed to the annual value of $34.8 million for FY2025, which is 1425.66% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Shares Outstanding (Weighted Average) amounted to $34.8 million in Q2 2025, which was up 1425.66% from $37.0 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Shares Outstanding (Weighted Average) peaked at $37.0 million during Q1 2025, and registered a low of $29.3 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $30.1 million (2023), whereas its average is $30.8 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 45.26% in 2021, then soared by 2142.83% in 2025.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Shares Outstanding (Weighted Average) stood at $29.5 million in 2021, then increased by 0.55% to $29.6 million in 2022, then increased by 2.78% to $30.5 million in 2023, then grew by 12.81% to $34.4 million in 2024, then grew by 1.33% to $34.8 million in 2025.
  • Its last three reported values are $34.8 million in Q2 2025, $37.0 million for Q1 2025, and $34.4 million during Q4 2024.